Allogeneic CAR.BiTE γδT (CAR001) For Solid tumers

Model: CAR001

Exhibitor: EVER SUPREME BIO TECHNOLOGY CO., LTD.

Booth No: N116

Characteristic

CAR001 is the first allogeneic γδ T cell CAR-T therapy in China prepared using mRNA technology, and is designed specifically for the treatment of recurrent and refractory solid tumors. Unlike the existing autologous CAR-T on the market, which is limited to the treatment of blood cancer, has a time-consuming process and has significant side effects, CAR001 is derived from allogeneic cells, is non-virally transferred, can be prefabricated in large quantities, and has the potential for immediate use and scalability. In addition, CAR001 targets HLA-G tumor antigen and is expected to break through the limitations of traditional CAR-T in the application of solid tumors.